An Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 After a Single Intramuscular Injection
Latest Information Update: 05 Jun 2023
Price :
$35 *
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease; Restless legs syndrome
- Focus Adverse reactions
- Sponsors Luye Pharma Group
- 04 Jan 2021 Status changed from not yet recruiting to recruiting, according to a Luye Pharma media release.
- 26 Oct 2020 New trial record